Please login to the form below
FDA awards grant for cancer drug study
The US FDA has awarded a $1.6m grant under its orphan drugs programme to a Alabama-based biotech company Egen to help the company with clinical trials of a potential new therapy for ovarian cancer
The US Food and Drug Administration (FDA) has awarded a $1.6m grant under its orphan drugs programme to a small, Alabama-based biotech company called Egen to help the company with clinical trials of a potential new therapy for ovarian cancer.
The four-year grant is intended to assist in the phase II clinical development of the privately held company's lead product, Egen-001, which is being developed for the treatment of advanced recurrent ovarian cancer.
The drug is an interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 enhances the body's immune system against cancer and inhibits tumour blood supply, according to Egen.
The product has completed two phase I trials: one as monotherapy in platinum-resistant ovarian cancer patients, and the other in combination with carboplatin/docetaxel chemotherapy in platinum-sensitive ovarian cancer patients.
The FDA granted orphan drug status to Egen-001 in 2005. The status, which is reserved for drugs intended to treat diseases that affect fewer than 200,000 Americans, carries a number of benefits, including seven years of US marketing exclusivity, tax breaks and eligibility for help with clinical trial costs.
This is Egen's second grant for the drug from the FDA. The first, totaling $1m, was awarded in 2005.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- EU “still interested” in Valneva COVID vaccine despite UK snub
- David Hunt launches independent agency The Considered
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- US demand for COVID-19 antibody treatments rising fast
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Embattled Biogen talks up Aduhelm
- Robust Review: COVID19 Assessment
- Market Access Transformation (MAT) Secures First Institutional Funding Led by Silversmith Capital Partners
- IBD Registry wins Communiqué award for COVID-19 tool
- Havas Life Medicom named Agency Digital Team and leads agency wins at PM Digital Awards
- New data for Tecentriq in early-stage lung cancer
- Strong five-year survival data for Kisqali in breast cancer
- David Hunt launches independent agency The Considered
- WHO to test three more potential COVID-19 treatments
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- Nicky Hutchens appointed as deputy managing director at Four Health
- FDA clears BMS/AZ's dapagliflozin at second attempt
- Lucid Group celebrates a double win at Communiqué 2021
PMHub
Havas Life Medicom
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
